Dr. Yeatman’s experience spans from clinical medicine to clinical and translational research, to personalized medicine, to hospital and large program administration to business development. He has been a physician scientist and clinical surgeon for nearly 30 years. He has held multiple academic and ascending executive leadership roles at the University of South Florida, Moffitt Cancer Center, Gibbs Cancer Center, Intermountain Healthcare, and the University of Utah/Huntsman Cancer Institute. He served as Chief Science Officer for the NASA-funded Center for Advancement of Science in Space that identified scientific projects that flew to the International Space Station. He led the development of Moffitt’s signature precision medicine program, Total Cancer Care, funded by a $100M grant from Merck. He also founded M2Gen, a biomarker development company, and the Guardian Research Network, a nationwide consortium dedicated to bringing clinical trials to the community. Continuously funded by the NCI since 1994, Dr. Yeatman has focused on the genomics of colon cancer, biomarker development, and drug repurposing. He is currently a Professor of Surgery at the University of South Florida and ACD for Translational Research and Innovation at the Tampa General Hospital Cancer Institute.